晚期高级别浆液性卵巢癌接受腹腔内与静脉全身治疗首次复发部位的描述
这项回顾性队列研究纳入208例III或IV期高级别浆液性卵巢癌患者,均接受理想初次肿瘤细胞减灭术后行紫杉醇联合铂类化疗,其中152例(73%)接受腹腔内化疗、56例(27%)接受静脉化疗。腹腔内化疗与腹腔内复发减少相关(OR 0.33,95%CI 0.17-0.64),且2年后复发风险低于静脉化疗(HR 0.30,95%CI 0.17-0.53)。
要点
- 腹腔内化疗与腹腔内复发减少相关(OR 0.33,95%CI 0.17-0.64)。
- 诊断时腹膜外病变与腹膜外复发增加相关(OR 4.09,95%CI 1.84-9.10)。
- 2年后腹腔内化疗组复发风险低于静脉化疗组(HR 0.30,95%CI 0.17-0.53)。
核心结论
- 对于理想初次肿瘤细胞减灭术后的高级别浆液性卵巢癌患者,与静脉化疗相比,腹腔内化疗与腹腔内复发减少及2年后复发风险降低相关。
研究设计与样本
- 回顾性队列研究,纳入2010年至2020年间在一家三级医疗机构接受理想初次肿瘤细胞减灭术并后续接受紫杉醇联合铂类化疗(腹腔内或静脉)的III或IV期高级别浆液性卵巢癌患者,共208例。
主要发现
- 208例中152例(73%)接受腹腔内化疗,56例(27%)接受静脉化疗。
- 腹腔内化疗与腹腔内复发减少相关(OR 0.33,95%CI 0.17-0.64)。
- 诊断时腹膜外病变是唯一与腹膜外复发增加相关的因素(OR 4.09,95%CI 1.84-9.10)。
- 诊断时淋巴结病变与淋巴结复发增加相关(OR 4.54,95%CI 2.35-9.04)。
- 初次肿瘤细胞减灭术时肉眼残留病变与淋巴结复发增加相关(OR 2.43,95%CI 1.18-5.11)。
临床怎么用
- 作者认为,对于理想初次肿瘤细胞减灭术后的高级别浆液性卵巢癌患者,腹腔内化疗与腹腔内复发减少及2年后复发风险降低相关,这突显了其在腹膜局限性疾病中的价值。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To investigate the association of adjuvant intraperitoneal (IP) and intravenous (IV) chemotherapy with location and timing of recurrence in patients with advanced high grade serous ovarian cancer (HGSOC). METHODS: This retrospective cohort study includes patients with stage III or IV HGSOC who underwent optimal primary cytoreductive surgery (PCS) and subsequently received paclitaxel and platinum-based chemotherapy, either IP or IV, at a tertiary care institution between 2010 and 2020. We performed adjusted multivariable logistic regressions to evaluate locations of first recurrence, and adjusted Cox proportional hazards models to assess the association of adjuvant chemotherapy administration and progression free survival. RESULTS: 208 patients met inclusion criteria, of whom 152 (73 %) received IP and 56 (27 %) received IV chemotherapy. IP chemotherapy was associated with decreased intraperitoneal recurrence (odds radio (OR) 0.33 (95 % confidence interval (CI) 0.17-0.64). Extraperitoneal disease at diagnosis was the only factor associated with increased extraperitoneal recurrence (OR 4.09 (95 % CI 1.84-9.10)). Presence of lymph node disease at diagnosis and gross residual disease at PCS were associated with increased lymph node recurrence (OR 4.54 (95 %CI 2.35-9.04) and OR 2.43 (95 %CI 1.18-5.11) respectively). After two years, the risk of recurrence was lower for patients who received IP, compared with IV, chemotherapy (HR 0.30 (95 % CI 0.17-0.53)). CONCLUSIONS: For patients with HGSOC after optimal PCS, IP chemotherapy is associated with decreased intraperitoneal recurrence and decreased risk of recurrence after 2 years compared with IV chemotherapy. This highlights its value in peritoneal restricted disease.
引用
- Lindgren A, Benseler A, Hogen L, et al. Description of first recurrence in advanced stage high grade serous ovarian cancer receiving intraperitoneal versus intravenous systemic treatment. Gynecol Oncol. 2025. PMID: 41172551. doi:10.1016/j.ygyno.2025.10.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。